Ouster

OUST · NASDAQ

$29.65+$0.79 (+2.74%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $28.86

OUST analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy4
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $60.59 (+104.3% upside)

Low: $52.52
Now: $29.65
High: $78.75

Upgrades and downgrades

The latest rating actions, newest first

OUST analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Rosenblatt	Aug 27, 2026	Maintains	Buy	$53.00	53%
Rosenblatt	Aug 7, 2026	Maintains	Buy	$53.00	53%
Northland Capital Markets	Jul 21, 2026	Maintains	Outperform	$38.00 → $60.00	71%
Oppenheimer	Jul 15, 2026	Maintains	Outperform	$42.00 → $57.00	37%
Rosenblatt	May 27, 2026	Maintains	Buy	$40.00 → $53.00	53%
Amerx	May 11, 2026	Initiates	Buy	$43.00	31%
Cantor Fitzgerald	May 7, 2026	Downgrade	Overweight → Neutral	—	59%
Rosenblatt	Mar 3, 2026	Maintains	Buy	$40.00	53%
Cantor Fitzgerald	Nov 7, 2025	Upgrade	Neutral → Overweight	$30.00 → $33.00	59%
Cantor Fitzgerald	Nov 6, 2025	Upgrade	Neutral → Overweight	—	59%

The case for and against

Updated Oct 16, 2026

Bull case

Ouster is benefiting from rapid adoption of its REV8 LiDAR and Stereolabs cameras, with design wins in autonomous agriculture, counter-UAS, and smart infrastructure broadening its addressable market. The company’s 2Q26 revenue rose to $54.6M, up 55.9% Y/Y, while non-GAAP gross margin reached 53.5% and the adjusted EBITDA loss improved to ($4.45M), signaling stronger operating leverage alongside expanding scale. With more than 17,000 sensors shipped, multiple $1M+ REV8 orders, and exposure to industrial, robotics, and autonomous vehicle applications, the business appears well positioned for sustained 30%+ revenue growth.

Bear case

Ouster is facing a cautious outlook because its Rev8 and Stereolabs customer wins are converting more slowly into volume production, which delays the revenue scale needed to support profitability. The company’s 3Q26 guidance of $54.5M-$57.5M in revenue, or $56.0M at the midpoint, came in below estimates, even as management reaffirmed about $5M of FY26 royalty revenue and expects 3Q operating expenses to rise 5%-8% Y/Y. Gross margin and operating leverage also appear at risk if higher-volume deployments carry lower ASPs or if manufacturing cost reductions lag the ramp to production volumes by quarter-end.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.